$6.14
▲ +$0.13
(+2.16%)
Vol 329K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$29.3M
ROE
-394.5%
D/E
91.68
Beta
-0.75
52W
$3–$6
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
88.9%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 0.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.64 | $-0.93 | $-0.29 |
| Sep 2025 | $-0.83 | $-1.35 | $-0.52 |
| Jun 2025 | $-0.89 | $-1.09 | $-0.20 |
| Mar 2025 | $-1.03 | $-1.04 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$4.1M | -$6.1M | -$3.8M | -$4.8M | -$7.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -232.2% | -229.8% | -232.2% | -232.2% | -232.2% | -394.5% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 93.15 | 85.13 | 93.15 | 93.15 | 93.15 | 91.68 |
| Current Ratio | 1.52 | 1.87 | 1.52 | 1.52 | 1.52 | 1.26 |
Key Ratios
ROA (TTM)
-172.0%
P/B
2.1
EPS (TTM)
$-5.35
CF/Share
$-1.52
52W High
$6.01
52W Low
$3.20
$3.20
52-Week Range
$6.01
Financial Health
Free Cash Flow
-$4.2M
Net Debt
-$1.5M
Cash
$6.1M
Total Debt
$4.6M
As of Sep 30, 2025
How does CING compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
CING valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
2.1
▲
0%
above
peers
(2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
CING profitability vs Pharmaceuticals peers
ROE
-394.5%
▼
627%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-172.0%
▼
359%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
CING financial health vs Pharmaceuticals peers
D/E ratio
91.7
▲
5853%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
1.3
▼
62%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
-0.8
▼
180%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
CING fundamentals radar
CING
Peer median
Industry
CING profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CING vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
SCHAFFER SHANE J.
Chief Executive Officer · Mar 09
6862 shs
CALLAHAN JENNIFER L.
Chief Financial Officer · Mar 09
15329 shs
SILVA RAUL R.
Officer · Mar 09
4526 shs
BRAMS MATTHEW
Officer · Mar 09
4526 shs
PATEL NILAY DAHYABHAI J.D.
Officer · Mar 09
5475 shs
WERTH PETER J.
Director · Feb 06
19455 shs
SCHAFFER SHANE J.
Chief Executive Officer · Feb 06
6809 shs
CALLAHAN JENNIFER L.
Chief Financial Officer · Feb 06
4864 shs
BRAMS MATTHEW
Officer · Feb 06
1946 shs
Last 90 days
Top Holders
Top 5: 5.17%Vanguard Group Inc
1.86%
$968K
Kestra Advisory Services, L…
1.50%
$780K
Geode Capital Management, L…
0.75%
$390K
DRW Securities, LLC
0.72%
$375K
UBS Group AG
0.34%
$177K
As of Dec 31, 2025
Latest News
International Stocks Are Trouncing Growth Stocks and This ETF Pays You a …
Yahoo Finance · Apr 05
Premier League clubs facing £80m shirt sponsor void amid gambling ban
The Guardian · Apr 05
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market
Nasdaq · Apr 03
Multifamily properties in Chicago, LA and Florida moved to servicing
Yahoo Finance · Apr 03
OpenAI Snaps Up TBPN, Slashes ChatGPT Pricing As Secondary Market Interest Fades
ZeroHedge · Apr 02